Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount

European Journal of Nuclear Medicine

Volumn 26, Issue 7, 1999, Pages 693-698

  De Jong, Marion ^a   Breeman, Wout A P ^a   Bernard, Bert F ^a   Van Gameren, Arthur ^a   De Bruin, Elisa ^a   Bakker, Willem H ^a   Van der Pluijm, Marcel E ^a   Visser, Theo J ^a   Mäcke, Helmut R ^b   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Kantonspital Basel ^*  (Switzerland)

Author keywords

DOTA0,Try3 octreotide; Peptide mass; Somatostatin receptors; Tumour uptake

Indexed keywords

CHELATING AGENT; INDIUM 111; OCTREOTIDE; PENTETATE INDIUM IN 111; PEPTIDE; RADIOISOTOPE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TETRAAZACYCLODODECANETETRAACETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 90;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HYPOPHYSIS; ISOTOPE LABELING; MALE; NONHUMAN; PANCREAS TUMOR; RADIOTHERAPY; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SCINTIGRAPHY; STOMACH; TARGET ORGAN; TEMPERATURE DEPENDENCE; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; INDIUM RADIOISOTOPES; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION;

EID: 0032813383     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050439     Document Type: Article

References (16)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med1993; 20: 716-731.
2. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, ReubiJC. Somatostatin receptor scintigraphy. In: Freeman M, ed.Nuclear medicine annual. New York: Raven Press; 1995:1-50.
3. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, PostemaPTE, De Herder WW, Valkema R, Kwekkeboom DJ. Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 1996; 57: 57-61.
4. Krenning EP, De Jong M, Valkema R, Van Eijck CHJ. Breastimaging with radiolabelled peptides; prospects for the future.In: Taillefer R et al., eds. Radionuclide imaging of the breast:clinical applications. New York: Marcel Dekker; 1998:235-265.
5. Stolz B, Smith-Jones PM, Albert R, Tolcsvai L, Briner U,Ruser B, Mäcke H, Weckbecker G, Bruns C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy ofcancer. Digestion 1996; 57: 17-21.
6. Anderson CJ, Sherman ELC, McCarthy DW, Bass LA, JonesLA, Cristel ME, Lanahan MV, Shefer RE, Klinkowstein RE,Welch MJ. Radiotherapy studies of Cu-64-labelled TETA-oct-reotide in tumour-bearing rats. J Nucl Med 1996; 37:128-129P.
7. Breeman WAP, Kwekkeboom DJ, Kooij PPM, Bakker WH,Hofland LJ, Visser TJ, Ensing GJ, Lamberts SWJ, KrenningEP. Effect of dose and specific activity on tissue distributionof indium-111-pentetreotide in rats. J Nucl Med 1995; 36:623-627.
8. Kooij PPM, Kwekkeboom DJ, Breeman WAP, Reijs AEM,Bakker WH, Lamberts SWJ, Visser TJ, Krenning EP. The effects of specific activity on tissue distribution of [In-111-DTPA-D-Phe1]-octreotide in humans. J Nucl Med 1994; 35:226P.
9. 3]octreotide, apromising Somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
10. 111In-labelled somatostatin-analogs for tumour scintigraphy and radionuclide therapy. Cancer Res 1998; 58: 437-441.
11. 3]octreotide eradicates experimental ratpancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25:668-674.
12. Otte A, Jermann E, Béhé M, Goetze M, Bucher HC, RoserHW, Heppeler A, Müller-Brand J, Mäcke HR. DOTATOC: apowerful new tool for receptor-mediated radionuclide-therapy.Eur J Nucl Med 1997; 24: 792-795.
13. 3]octreotide:peptides for somatostatin receptor-targeted scintigraphy andradionuclide therapy. Nucl Med Commun 1998; 19: 283-288.
14. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K,Someya Y, Ihara Y, Li Q, Imura H, Seino S, Seino Y. Cloning,functional expression and pharmacological characterization ofa fourth (hSSTR4) and a fifth (hSSTR5) human somatostatinreceptor subtype. Biochem Biophys Res Commun 1993; 195:844-852.
15. Kubota A, Yamada Y, Kagimoto S. Identification of somatostatin receptor subtypes and an implication for the efficacy ofsomatostatin analogue SMS 201-995 in treatment of humanendocrine tumors. J Clin Invest 1994; 93: 1321-1325.
16. 111In-octreoscan in a rat tumour model. Eur J Nucl Med1998; 25: 883p.